Rein Therapeutics, Inc. 8-K

What Happened
Rein Therapeutics, Inc. (RNTX) filed a Form 8-K on February 19, 2026 reporting that Manuel C. Alves Aivado, M.D., Ph.D., notified the company on February 16, 2026 of his decision to resign as a member of the Board of Directors, effective immediately. The filing states Dr. Aivado’s resignation was not due to any disagreement with the company on matters relating to its operations, policies or practices.

Key Details

• Filing: Form 8-K (Item 5.02) filed February 19, 2026.
• Resignation date: Dr. Aivado notified the company on February 16, 2026; resignation effective immediately.
• Reason: Company disclosure: resignation was not the result of any disagreement with the company on operations, policies, or practices.
• Role affected: Member of the Board of Directors (no other officer changes reported in this filing).

Why It Matters
Board departures are governance events investors watch because they can affect oversight and strategic direction. This filing confirms a board seat is now vacant and that the departure was not due to a reported dispute with management, which typically lowers concerns about internal conflict. Investors should monitor future filings or press releases for information about any replacement director or changes to board committees.